Rodman and Renshaw, a boutique investment bank focused on life science PIPEs and private placements, priced 8 million shares at $5 per share, the low end of the expected $5 to $7 range. Sandler O'Neill and Fox-Pitt Kelton are the joint book runners on the deal.
